Clinical trial
Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic…
NCT00288236 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00288236 |
|---|---|
| Title | Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO) |
| Official title | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed-Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/Day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled With Insulin |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Rimonabant (SR141716), Placebo |
| Enrollment | 368 |
| Start date | Jan 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Feb 7, 2006 |
| Last update posted | Apr 7, 2009 |
| Countries | Argentina, Australia, Canada, Chile, France, Germany, Italy, Netherlands, Russia, South Africa, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: